Form 4: Rhythm Pharmaceuticals Executive Trades Stock Options
Statement of Changes in Beneficial Ownership
Christopher Paul German, Corporate Controller & CAO of Rhythm Pharmaceuticals, Inc., reported significant stock option transactions on May 15, 2026.
Summary
- Christopher Paul German, Corporate Controller & CAO of Rhythm Pharmaceuticals, Inc., engaged in several transactions involving common stock and stock options on May 15, 2026.
- He acquired a total of 4,435 shares of common stock through the exercise of stock options at prices ranging from $17.97 to $56.69 per share.
- These acquisitions resulted in an increase in his directly held common stock.
- Additionally, he disposed of 4,643 shares of common stock at a price of $92.21 per share.
- The filing also details the grant dates and vesting schedules for the stock options exercised.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider stock option exercises and sales, which are common for executives and do not inherently signal a strong positive or negative outlook for the company.
Positives
- Acquisition of 4,435 shares of common stock through option exercises, indicating potential belief in the company's future value.
- Disposal of 4,643 shares at a price of $92.21, suggesting a profitable exit for a portion of his holdings.
Negatives
- A net decrease in directly held common stock by 208 shares (4,435 acquired - 4,643 disposed).
Future Outlook
The filing details the vesting schedules and expiration dates of various stock options, indicating potential future exercises and holdings adjustments by the reporting person.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the buying and selling activities of company executives and directors. These transactions can offer insights into management's confidence in the company's prospects.
Stakeholder Impact
- Shareholders: The transactions provide transparency into insider activity, which can influence investor sentiment. The sale of shares at a profit may be viewed positively by some, while the net reduction in holdings could be a point of observation.
Key Dates
| Date | Description |
|---|---|
| 05/15/2026 | Date of earliest transaction reported |
| 02/13/2035 | Expiration date for stock options granted on February 14, 2025 |
| 02/15/2034 | Expiration date for stock options granted on February 16, 2024 |
| 04/03/2033 | Expiration date for stock options granted on April 4, 2023 |
| 03/20/2027 | End date for quarterly vesting installments for stock options granted on April 4, 2023 |
| 05/19/2026 | Date of signature on the filing |
Keywords
Form 4, SEC Filing, Rhythm Pharmaceuticals, RYTM, Stock Options, Beneficial Ownership, Insider Trading, Christopher Paul German, Corporate Controller, CAO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.